HRB NCTO National Study Feasibility Programme
Study feasibility is a process through which a clinical trial sponsor (or representative e.g. Clinical Research Organisations) identifies potential investigator sites and evaluates if they are suitable to conduct the clinical trial. HRB NCTO provides a service to streamline the clinical trial investigator site identification and study feasibility process nationally, delivering consistency and efficiency in the process. Our study feasibility service is free of charge with an aim of secure more research opportunities for Irish patients and to ensure that Ireland is recognised internationally as a preferred location for clinical trials and covers all disease areas.
The HRB NCTO National Study Feasibility Programme connects academic and industry sponsors with potential investigators. HRB NCTO act as the channel through which study feasibility assessments can be distributed and completed efficiently. The HRB NCTO Investigator Membership Database and Clinical Research Facility/Centre (CRF/C) network is utilised to significantly reduce the time taken to identify investigator sites and to assess study feasibility. For Oncology Studies, we collaborate with Cancer Trials Ireland and Cancer Trials Research Units across Ireland on these feasibility assessments.
The programme is actively managed by the Trial Platform Lead with an aim to feedback to the source within two weeks of initial receipt of a feasibility request. Specific NCTO staff based in these units support Investigators with the rapid & accurate completion of the feasibility assessment and timely delivery of study start-up and first patient first visit (FPFV).
To place a study feasibility service request:
- Protocol synopsis
- Study feasibility questionnaire (if available)
- Study timelines, including accrual timelines (local and international)
- Any specific trial related questions which are critical to evaluating feasibility (e.g. Standard treatments, study assessments etc.)
- Confirm if the study is definitely being placed in Ireland, or if the applicant is currently bidding for the study
- Confidential disclosure agreement (if available)
- A list of potential sites (if available) and confirmation of which sites have been approached to date